Research ArticlePediatric Rheumatology

Glucocorticoid: Major Factor for Reduced Immunogenicity of 2009 Influenza A (H1N1) Vaccine in Patients with Juvenile Autoimmune Rheumatic Disease

NADIA E. AIKAWA, LUCIA M.A. CAMPOS, CLOVIS A. SILVA, JOZELIO F. CARVALHO, CARLA G.S. SAAD, GUILHERME TRUDES, ALBERTO DUARTE, JOAO L. MIRAGLIA, MARIA do CARMO S. TIMENETSKY, VILMA S.T. VIANA, IVAN L.A. FRANÇA, ELOISA BONFA and ROSA M.R. PEREIRA
The Journal of Rheumatology January 2012, 39 (1) 167-173; DOI: https://doi.org/10.3899/jrheum.110721

REFERENCES

  1. 1.↵
    1. Faco MM,
    2. Leone C,
    3. Campos LM,
    4. Febrônio MV,
    5. Marques HH,
    6. Silva CA
    . Risk factors associated with the death of patients hospitalized for juvenile systemic lupus erythematosus. Braz J Med Biol Res 2007;40:993–1002.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Ioannou Y,
    2. Isenberg DA
    . Immunization of patients with systemic lupus erythematosus: The current state of play. Lupus 1999;8:497–501.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Maddison PJ,
    2. Isenberg DA,
    3. Woo P,
    4. Glass DN
    1. Isenberg DA,
    2. Horsfall AC
    . Systemic lupus erythematosus in adults. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford textbook of rheumatology. 2nd ed. New York: Oxford University Press; 1998:1157.
  4. 4.↵
    1. Centers for Disease Control and Prevention (CDC)
    . Update: influenza activity — United States, August 30, 2009–January 9, 2010. MMWR Morb Mortal Wkly Rep 2010;59:38–43.
    OpenUrlPubMed
  5. 5.↵
    1. Fiore AE,
    2. Uyeki TM,
    3. Broder K,
    4. Finelli L,
    5. Euler GL,
    6. Singleton JA,
    7. et al.
    Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:1–62. [Erratum, MMWR Recomm Rep 2010;59:1147; MMWR Recomm Rep 2010;59:993.]
    OpenUrlPubMed
  6. 6.↵
    1. Kanakoudi-Tsakalidou F,
    2. Trachana M,
    3. Pratsidou-Gertsi P,
    4. Tsitsami E,
    5. Kyriazopoulou-Dalaina V
    . Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001;19:589–94.
    OpenUrlPubMed
  7. 7.↵
    1. Malleson PN,
    2. Tekano JL,
    3. Scheifele DW,
    4. Weber JM
    . Influenza immunization in children with chronic arthritis: A prospective study. J Rheumatol 1993;20:1769–73.
    OpenUrlPubMed
  8. 8.↵
    1. Ogimi C,
    2. Tanaka R,
    3. Saitoh A,
    4. Oh-Ishi T
    . Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J 2011;30:208–11.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Bate J,
    2. Yung CF,
    3. Hoschler K,
    4. Sheasby L,
    5. Morden J,
    6. Taj M,
    7. et al.
    Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. Clin Infect Dis 2010;51:e95–104.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Esposito S,
    2. Meregalli E,
    3. Daleno C,
    4. Ghio L,
    5. Tagliabue C,
    6. Valzano A,
    7. et al.
    An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant 2011;26:2018–24.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Hochberg MC
    . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Petty RR,
    2. Southwood T,
    3. Manners P,
    4. Baum J,
    5. Glass DN,
    6. Goldenberg J,
    7. et al.
    International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision Edmonton 2001. J Rheumatol 2004;31:390–2.
    OpenUrlFREE Full Text
  13. 13.↵
    1. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
    . Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581–9.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Bohan A,
    2. Peter JB
    . Polymyositis and dermatomyositis. N Engl J Med 1975;292:344–7.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Criteria for diagnosis of Behçet’s disease
    . International Study Group for Behçet’s Disease. Lancet 1990;335:1078–80.
    OpenUrlPubMed
  16. 16.↵
    1. Ozen S,
    2. Pistorio A,
    3. Iusan SM,
    4. Bakkaloglu A,
    5. Herlin T,
    6. Brik R,
    7. et al.
    EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010;69:798–806.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Ozen S,
    2. Ruperto N,
    3. Dillon MJ,
    4. Bagga A,
    5. Barron K,
    6. Davin JC,
    7. et al.
    EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis 2006;65:936–41.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Kendal AP,
    2. Pereira MS,
    3. Skehel JJ
    , eds. Concepts and procedures from laboratory-based influenza surveillance. Atlanta: Centers for Disease Control and Prevention; 1982.
  19. 19.↵
    1. Oh CE,
    2. Lee J,
    3. Kang JH,
    4. Hong YJ,
    5. Kim YK,
    6. Cheong HJ,
    7. et al.
    Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: A prospective, open-label, multi-center trial. Vaccine 2010;28:5857–63.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Liang XF,
    2. Wang HQ,
    3. Wang JZ,
    4. Fang HH,
    5. Wu J,
    6. Zhu FC,
    7. et al.
    Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: A multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010;375:56–66.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Saad CGS,
    2. Borba EF,
    3. Aikawa NE,
    4. Silva CA,
    5. Pereira RMR,
    6. Calich AL,
    7. et al.
    Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011;70:1068–73.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Setti M,
    2. Fenoglio D,
    3. Ansaldi F,
    4. Filaci G,
    5. Bacilieri S,
    6. Sticchi L,
    7. et al.
    Flu vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009;27:3367–72.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Conti F,
    2. Rezai S,
    3. Valesini G
    . Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 2008;8:124–8.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Iliopoulos AG,
    2. Tsokos GC
    . Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum 1996;25:318–36.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Holvast A,
    2. van Assen S,
    3. de Haan A,
    4. Huckriede A,
    5. Benne CA,
    6. Westra J,
    7. et al.
    Effect of a second, booster, influenza vaccination on antibody responses in quiescent systemic lupus erythematosus: an open, prospective, controlled study. Rheumatology 2009;48:1294–9.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Holvast A,
    2. van Assen S,
    3. de Haan A,
    4. Huckriede A,
    5. Benne CA,
    6. Westra J,
    7. et al.
    Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum 2009;60:2438–47.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Kasapçopur O,
    2. Cullu F,
    3. Kamburoglu-Goksel A,
    4. Cam H,
    5. Akdenizli E,
    6. Calykan S,
    7. et al.
    Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1128–30.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. De Paepe B,
    2. Creus KK,
    3. De Bleecker JL
    . Chemokine profile of different inflammatory myopathies reflects humoral versus cytotoxic immune responses. Ann NY Acad Sci 2007;1109:441–53.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Holvast A,
    2. Stegeman CA,
    3. Benne CA,
    4. Huckriede A,
    5. Wilschut JC,
    6. Palache AM,
    7. et al.
    Wegener’s granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2009;68:873–8.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Kunisaki KM,
    2. Janoff EN
    . Influenza in immunosuppressed populations: A review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009;9:493–504.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Hanania NA,
    2. Sockrider M,
    3. Castro M,
    4. Holbrook JT,
    5. Tonascia J,
    6. Wise R,
    7. et al; and
    8. American Lung Association Asthma Clinical Research Centers
    . Immune response to influenza vaccination in children and adults with asthma: Effect of corticosteroid therapy. J Allergy Clin Immunol 2004;113:717–24.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Fomin I,
    2. Caspi D,
    3. Levy V,
    4. Varsano N,
    5. Shalev Y,
    6. Paran D,
    7. et al.
    Vaccination against influenza in rheumatoid arthritis: The effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006;65:191–4.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Wallin L,
    2. Quintilio W,
    3. Locatelli F,
    4. Cassel A,
    5. Silva MB,
    6. Skare TL
    . Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol Port 2009;34:498–502.
    OpenUrlPubMed
  34. 34.↵
    1. Iorio AM,
    2. Alatri A,
    3. Francisci D,
    4. Preziosi R,
    5. Neri M,
    6. Donatelli I,
    7. et al.
    Immunogenicity of influenza vaccine (1993–94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. Vaccine 1997;15:97–102.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Crum-Cianflone NF,
    2. Eberly LE,
    3. Duplessis C,
    4. Maguire J,
    5. Ganesan A,
    6. Faix D,
    7. et al.
    Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: A prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011;52:138–46.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    1. Tremblay CL,
    2. Rouleau D,
    3. Fortin C,
    4. Toma E,
    5. Sylla M,
    6. Cyr L,
    7. et al.
    Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients. Vaccine 2011;29:1359–63.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. EMEA. European Committee for Proprietary Medicinal Products
    . Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/VEG/4717/03). London: European Agency for the Evaluation of Medicinal Products; 2004. [Internet. Accessed Sept 28, 2011.] Available from: http://archives.who.int/prioritymeds/report/append/62EMEAguidelines.pdf
  38. 38.↵
    1. EMEA. Committee for Proprietary Medicinal Products
    . Note for guidance on harmonisation of requirements for influenza vaccines. London: European Agency for the Evaluation of Medicinal Products; 1996. Publication no. CPMP/BWP/214/96. [Internet. Accessed Sept 28, 2011.] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf
  39. 39.↵
    1. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research
    . Guidance for industry: Clinical data needed to support the licensure of pandemic influenza vaccines. May 2007. [Internet. Accessed Sept 28, 2011.] Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091985.pdf
  40. 40.↵
    1. Djilali-Saiah I,
    2. Lapierre P,
    3. Vittozi S,
    4. Alvarez F
    . DNA vaccination breaks tolerance for a neo-self antigen in liver: A transgenic murine model of autoimmune hepatitis. J Immunol 2002;169:4889–96.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Bookmark this article

Jump to section